search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- corporate advisors
Highlights
The Company is experiencing excellent sales growth, flagship product Decapinol® (gingivitis/gum disease) nearly trebled its sales revenues during the year.
- EBITDA profit £1.3m:
2007 loss £(1.1)m - Robust product portfolio:
Eight products that contributed more than £1.0m revenue per annum - Continued growth of own sales and marketing operations:
16% growth in revenues through own sales and marketing operations,
now representing 45% of total revenues - Streamlined marketing operations in France and UK
- Continued geographical expansion through marketing partner network:
46% growth in revenues through marketing partners
20 product launches in 12 months, covering nine products in 17 markets - Continued pipeline advancement:
Seven new product registrations
Ten new filings in the EU and US
